Oral semaglutide was cost-effective versus 5 of 6 injectable GLP-1 receptor agonists for achieving diabetes blood sugar targets in the US market.
5 of 6injectable GLP-1 drugs were less cost-effective than oral semaglutide for achieving diabetes targets
What the researchers found
The cost-of-control analysis compared oral semaglutide 14 mg against six injectable GLP-1 receptor agonists for type 2 diabetes. The calculation divides annual drug cost by the proportion of patients reaching HbA1c targets.
For the HbA1c ≤6.5% target, costs per patient achieving control: injectable semaglutide 1 mg was cheapest at $15,430, followed by oral semaglutide 14 mg at $17,383. All others (dulaglutide, exenatide once-weekly and twice-daily, liraglutide, lixisenatide) cost more per controlled patient.
For HbA1c <7.0%: injectable semaglutide 1 mg led at $12,627, followed by oral semaglutide at $13,493. The pattern was consistent.
Oral semaglutide was likely cost-effective versus all comparators except injectable semaglutide. This matters because some patients strongly prefer pills over injections.
Why it matters
Many patients with type 2 diabetes avoid injectable GLP-1 drugs despite their effectiveness. Oral semaglutide (Rybelsus) removes the injection barrier. This analysis shows the pill form is cost-effective compared to most injectables, supporting its use in patients who prefer oral medication.
The numbers in context
$15,430 injectable sema; $17,383 oral sema per patient at HbA1c≤6.5%; oral sema cost-effective vs 5/6 injectables
How the study worked
Cost-of-control analysis using efficacy data from the PIONEER clinical trial program and a published network meta-analysis. Annual US treatment costs were divided by the proportion of patients achieving HbA1c targets (≤6.5% and <7.0%). This is a short-term cost-effectiveness model, not a full health economic evaluation with quality-of-life or long-term outcomes.
Who was studied
Type 2 diabetes patients from PIONEER trials and network meta-analysis
What this study cannot tell us
This is a short-term model based on blood sugar targets only. It does not account for weight loss, cardiovascular benefits, or quality of life, all of which differ among GLP-1 drugs. Drug pricing varies by country and payer. The analysis uses US list prices, which may not reflect negotiated prices. No sensitivity analysis for price changes was described in the abstract.
How to read the evidence
Moderate evidence. Based on PIONEER clinical trial data with a validated cost-of-control methodology. Limited by not including weight loss or cardiovascular outcomes.
When this study was published
Published in 2020. Drug pricing and clinical data have evolved since this analysis.
The bigger picture
Many diabetes patients avoid injectable drugs despite their effectiveness. Oral semaglutide removes the injection barrier while maintaining comparable cost-effectiveness, potentially expanding the number of patients who benefit from GLP-1 therapy.
Questions still open
- How do real-world adherence differences between oral and injectable drugs affect cost-effectiveness?
- Will oral semaglutide pricing change as biosimilar GLP-1 drugs enter the market?
- Should cost-effectiveness analyses include weight loss and cardiovascular benefits?
Common questions
Is the oral semaglutide pill as effective as the injection?
Why would someone choose a pill over an injection?
Read the original research
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Journal of medical economics, 23(6), 650-658
Citation
Hansen, B B; Nuhoho, S; Ali, S N; Dang-Tan, T; Valentine, W J; Malkin, S J P; Hunt, B. (2020). Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.. Journal of medical economics, 23(6), 650-658. https://doi.org/10.1080/13696998.2020.1722678